SunTrust Banks Inc. restated their hold rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report released on Monday. SunTrust Banks Inc. currently has a $52.00 price target on the stock.

Several other research analysts also recently issued reports on the stock. Vetr upgraded shares of Sarepta Therapeutics from a sell rating to a hold rating and set a $17.28 target price on the stock in a research note on Monday, June 20th. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, June 21st. Wedbush reiterated an outperform rating and issued a $36.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, June 22nd. Jefferies Group reiterated an underperform rating and issued a $7.00 target price on shares of Sarepta Therapeutics in a research note on Saturday, June 25th. Finally, William Blair reiterated a market perform rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics currently has an average rating of Buy and a consensus price target of $63.31.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.06% on Monday, reaching $49.46. 383,066 shares of the company traded hands. The stock’s 50-day moving average is $45.66 and its 200-day moving average is $26.92. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73. The stock’s market capitalization is $2.37 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period last year, the company earned ($0.87) EPS. Equities research analysts expect that Sarepta Therapeutics will post ($4.23) EPS for the current year.

In other news, CEO Edward M. Md Kaye sold 40,179 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $2,410,740.00. Following the sale, the chief executive officer now directly owns 117,162 shares in the company, valued at approximately $7,029,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jayant Aphale sold 35,000 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the completion of the sale, the vice president now owns 21,490 shares in the company, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in SRPT. Eagle Asset Management Inc. boosted its stake in Sarepta Therapeutics by 67.5% in the third quarter. Eagle Asset Management Inc. now owns 593,455 shares of the company’s stock worth $36,444,000 after buying an additional 239,165 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares in the last quarter. Harbour Capital Advisors LLC purchased a new stake in Sarepta Therapeutics during the second quarter worth $335,000. Schwab Charles Investment Management Inc. boosted its stake in Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock worth $2,934,000 after buying an additional 2,766 shares in the last quarter. Finally, Stifel Financial Corp boosted its stake in Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock worth $441,000 after buying an additional 1,178 shares in the last quarter. Institutional investors and hedge funds own 65.06% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.